Core Viewpoint - The Hong Kong IPO market is experiencing unprecedented enthusiasm, highlighted by the record-breaking subscription multiples, with the recent listing of Golden Leaf International Group achieving over 11,500 times subscription, marking a new era in the market [2][5]. Group 1: IPO Market Dynamics - Golden Leaf International Group became the first stock in Hong Kong history to achieve over 11,500 times subscription, reflecting a surge in market interest [2][5]. - As of October 10, 2025, there have been 18 new stocks with subscription multiples exceeding 1,000 times, and the first-day drop rate for new stocks has decreased to 23.18%, the lowest in nearly nine years [4][8]. - The strong return of profit-making effects is supported by three pillars: institutional improvements, abundant market liquidity, and an increasing proportion of new economy companies [4][9]. Group 2: Subscription Trends - The year 2025 has seen a significant increase in the number of new stocks with subscription multiples exceeding 1,000 times, rising from 7% in 2024 to 26% in 2025 [7]. - The average first-day increase for newly listed stocks is 37.63%, with 46 out of 69 new stocks experiencing price increases on their debut [8][9]. - The highest first-day increase recorded was 330% for Golden Leaf International Group, showcasing the market's strong performance [8]. Group 3: Supportive Factors - Policy support includes continuous institutional innovations by the Hong Kong Stock Exchange, which have simplified approval processes and optimized pricing mechanisms [9]. - Global liquidity has been bolstered by the Federal Reserve's interest rate cuts, leading to increased capital flow into emerging markets, including Hong Kong [9]. - The IPO market is diversifying, driven by technology and consumer sectors, with new stocks generally focusing on high-growth areas such as pharmaceuticals, durable consumer goods, and renewable energy [9]. Group 4: Cornerstone Investors - In 2025, 57 new stocks had cornerstone investors participating, accounting for 86.4% of the total, with an average of 5.7 cornerstone investors per stock [10]. - The total amount subscribed by cornerstone investors reached 742 million HKD, representing over 40% of the total IPO fundraising [10]. - Major projects like Ningde Times and Zijin Mining attracted significant cornerstone investments, highlighting the preference for high-barrier, large-cap projects [12].

近期，港股打新市场沸腾。10月9日，港股新股金叶国际集团暗盘一度涨超800%。金叶国际集团此次公 开发售部分获超额认购逾9030倍，成为港股史上超额认购倍数最高的新股。 金叶国际集团的火爆申购是今年港股打新的一个缩影。截至10月9日，港股市场年内共有69只新股上 市，其中大行科工、长风药业、布鲁可、银诺医药-B、蜜雪集团5只新股网上发行认购倍数均超过5000 倍。同一时期内，港股新股首日破发率降至24%以下，创下九年来新低。 多位接受采访的人士表示，新经济明星股的集聚效应与市场流动性的显著改善，共同推动了本轮港股打 新市场的活跃。此外，8月4日，港交所关于优化首次公开招股市场定价及公开市场规定的新规正式生 效。这一规则也对平衡投资者结构、提升新股定价效率有一定作用。 新经济公司IPO频现千倍认购 无论是从新股供给数量还是从市场投资热情来看，今年港股IPO市场的活跃度和热度都远高于去年同 期。 杜先杰认为，金叶国际集团最终选择了10%的公开发售比例，这一结构在当前市场环境下尤为值得关 注。一方面，公司本次集资规模相对有限；另一方面，港股打新市场资金极为充裕，较低比例的公开发 售份额面对庞大的申购需求，客观上加剧 ...

张大伟 制图 ◎记者 唐燕飞 近期，港股打新市场沸腾。10月9日，港股新股金叶国际集团暗盘一度涨超800%。金叶国际集团此次公 开发售部分获超额认购逾9030倍，成为港股史上超额认购倍数最高的新股。 金叶国际集团的火爆申购是今年港股打新的一个缩影。截至10月9日，港股市场年内共有69只新股上 市，其中大行科工、长风药业、布鲁可、银诺医药-B、蜜雪集团5只新股网上发行认购倍数均超过5000 倍。同一时期内，港股新股首日破发率降至24%以下，创下九年来新低。 多位接受采访的人士表示，新经济明星股的集聚效应与市场流动性的显著改善，共同推动了本轮港股打 新市场的活跃。此外，8月4日，港交所关于优化首次公开招股市场定价及公开市场规定的新规正式生 效。这一规则也对平衡投资者结构、提升新股定价效率有一定作用。 新经济公司IPO频现千倍认购 无论是从新股供给数量还是从市场投资热情来看，今年港股IPO市场的活跃度和热度都远高于去年同 期。 杜先杰认为，金叶国际集团最终选择了10%的公开发售比例，这一结构在当前市场环境下尤为值得关 注。一方面，公司本次集资规模相对有限；另一方面，港股打新市场资金极为充裕，较低比例的公开发 售份额 ...

Core Insights - The Hong Kong IPO market experienced significant growth in the first three quarters of 2025, leading globally with 68 new listings and total fundraising of HKD 182.45 billion, representing increases of 51% and 227% year-on-year respectively [1][2] - The market saw a high level of oversubscription, with 98% of new stocks receiving excess subscriptions and 86% of these having oversubscription multiples exceeding 20 times, doubling from the previous year [1][4] - The decline in the first-day drop rate to 24% marks a nine-year low, with an average first-day return rate of 28%, significantly higher than the previous year's 10.82% [6][7] Market Activity - The number of new stocks with oversubscription multiples exceeding 1,000 reached 15, accounting for nearly 23% of the total, with the highest being Daheng Technology at 7558.40 times [2][3] - The pharmaceutical and durable consumer goods sectors were particularly favored, with several companies in these industries achieving high subscription rates [2][8] Regulatory Environment - The increase in market activity occurred in a post-regulatory environment, following the Hong Kong Securities and Futures Commission's new rules that ended the era of "high leverage" in IPO subscriptions [4][5] - The new regulations aimed to address issues of excessive leverage and chaotic funding practices, resulting in a healthier market structure [5][6] Investment Performance - The significant improvement in the profitability of new stocks is attributed to a combination of policy benefits, ample liquidity, and industry upgrades [7][8] - The performance of large new listings, such as Ningde Times, which saw a first-day increase of 16% and a cumulative rise of over 87% by September 30, highlights the strong market sentiment [6][7] Market Dynamics - The IPO market is driven by a dual engine of technology and consumer sectors, with the medical and pharmaceutical industries leading in the number of listings, while manufacturing accounted for over 30% of fundraising [8] - The diverse industry distribution enhances market resilience and attractiveness, moving away from reliance on a single sector [8]

Core Insights - The Hong Kong IPO market experienced significant growth in the first three quarters of 2025, leading globally with 68 new listings and total fundraising of HKD 182.45 billion, representing a 51% and 227% increase year-on-year respectively [1][4] - The high demand for new shares is evident, with 98% of new stocks being oversubscribed and 86% having oversubscription multiples exceeding 20 times, doubling from the previous year [2][4] - The current market activity is characterized by healthy growth following regulatory changes that ended the era of high-leverage IPO subscriptions, shifting the focus to intrinsic value recognition and natural capital inflow [4][8] New Share Subscription Trends - In the first three quarters of 2025, 15 new stocks had oversubscription multiples exceeding 1,000 times, accounting for nearly 23% of new listings, with the highest being Daheng Technology at 7,558.40 times [2][3] - The pharmaceutical and durable consumer goods sectors saw the most interest, with several biotech firms achieving significant oversubscription rates, indicating strong investor confidence in innovative drug companies [2][3] Market Performance Metrics - The first-day IPO failure rate dropped to 24%, the lowest in nine years, with an average first-day return of 28%, a substantial increase from 10.82% in the previous year [5][6] - Notably, large IPOs performed exceptionally well, with companies like Ningde Times seeing a first-day increase of 16% and cumulative gains exceeding 87% by September 30 [7] Policy and Market Dynamics - The surge in the IPO market is attributed to a combination of policy benefits, ample liquidity, and industry upgrades, with regulatory measures simplifying the listing process and enhancing market attractiveness [8][9] - The Hong Kong Stock Exchange has received 348 listing applications as of October 5, 2025, with ongoing efforts to optimize regulations and attract more overseas companies [8][9] Industry Structure and Appeal - The IPO landscape in Hong Kong is driven by a dual focus on technology and consumer sectors, with the medical and pharmaceutical industries leading in the number of listings, while manufacturing accounted for over 30% of fundraising [9]

Core Insights - The Hong Kong IPO market has experienced significant growth in the first three quarters of 2025, leading globally with 68 new listings and total fundraising of HKD 182.45 billion, representing a 51% and 227% increase year-on-year, respectively [1][4] - The market has seen a high level of oversubscription, with 98% of new stocks being oversubscribed and 86% having oversubscription multiples exceeding 20 times, doubling from the previous year [1][4] - The decline in the first-day drop rate to 24% marks a nine-year low, with an average first-day return of 28%, significantly up from 10.82% in the previous year [6][7] Market Activity - A total of 15 new stocks had oversubscription multiples exceeding 1,000 times, accounting for nearly 23% of the new listings, with the highest being Daheng Technology at 7,558.40 times [2][3] - The pharmaceutical and durable consumer goods sectors have been particularly favored, with several biotech companies achieving high oversubscription rates, indicating strong investor interest in innovative drug companies [2][3] Regulatory Environment - The recent surge in market activity is attributed to a healthier growth environment following regulatory changes that ended the era of high-leverage IPO subscriptions, with the Hong Kong Securities and Futures Commission implementing measures to curb excessive leverage [4][5] - The previous year saw only 2 new stocks with oversubscription multiples exceeding 1,000 times, highlighting the shift in market dynamics post-regulation [4][5] Investment Returns - The significant increase in first-day returns and the reduction in the drop rate have contributed to a more favorable investment environment, attracting more investors to the IPO market [6][7] - The performance of large new listings, such as NIO's H-shares, which saw a first-day increase of 16% and a cumulative rise of over 87% by September 30, has further enhanced the appeal of IPO investments [6][7] Market Drivers - The robust performance of the Hong Kong IPO market is driven by a combination of policy incentives, ample liquidity, and an evolving industrial landscape, with the medical and pharmaceutical sectors leading in new listings [7][8] - The Hong Kong Stock Exchange has received 348 listing applications as of October 5, 2025, indicating strong interest from companies, particularly in the technology and consumer sectors [7][8]

Core Viewpoint - Three new stocks, Xipuni, Zijin Gold, and Botai Che Lian, all experienced price increases during their dark pool trading, indicating positive market sentiment towards these IPOs [1][2]. Group 1: IPO Information - Longfeng Pharmaceutical (02652.HK) is set to issue 41.198 million shares, with 10% allocated for public sale and 90% for international placement, at an offering price of 14.75 HKD per share [4]. - The company has a market capitalization of approximately 60.77 billion HKD and a price-to-earnings ratio of 265 times [12]. - The minimum investment amount for a single lot of 500 shares is 7,449 HKD [4]. Group 2: Company Overview - Longfeng Pharmaceutical, established in January 2013 in Suzhou, focuses on the development of inhalation drug delivery technologies, particularly for respiratory diseases [4]. - The product pipeline includes treatments for asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis [4]. Group 3: Product Line and Market Performance - The core product CF017 (Budesonide inhalation suspension) is the top-selling inhalation drug in China, accounting for approximately 16% of the market share in 2024 [5][11]. - CF018 (Fluticasone nasal spray) is the first drug approved in China for moderate to severe allergic rhinitis, included in the national medical insurance directory as of December 2023 [6]. - Revenue from CF017 constituted 96.2% of total revenue in 2022, highlighting the company's reliance on a single product [9][10]. Group 4: Financial Performance - Longfeng Pharmaceutical's revenue grew from 349.1 million CNY in 2022 to an estimated 607.8 million CNY in 2024, with a compound annual growth rate of 31.9% [7]. - The company achieved profitability in 2023 with a net profit of 31.73 million CNY, but profits are projected to decline to 21.09 million CNY in 2024 [8]. Group 5: Competitive Landscape and Market Outlook - The market for budesonide products is becoming increasingly competitive, with nine products available in China as of 2025, including seven domestic brands [11]. - The global respiratory drug market is expected to grow from 99.9 billion USD in 2024 to 157.2 billion USD by 2033, with a compound annual growth rate of 5.2% [11]. - Longfeng Pharmaceutical is developing over 20 candidate products for global markets, including innovative therapies for CNS diseases and infections [11].

上周五下午17:00后各券商陆续公布三只新股的中签结果，但详细信息要等明天暗盘交易结束后，晚上22点港交所官方网站披露易发布的新股配发结果公 告。 | | 西普尼(02583.HK)-分配结果 | | | --- | --- | --- | | 定价 | HK$29.60 | | | 一手股数 | 100 | | | 一手市值 | HK$2960 | | | 申购股数(股) | 最小中签股数(股) | 最大中签股数() | | 甲组 | | | | 100-100,000 | 0 | 100 | | 乙组 | | | | 200,000 | 0 | 100 | | 300,000 | 100 | 200 | | 400,000 | 100 | 200 | | 530,000 | 100 | 200 | | | 仅供参考,详细结果可阅读港交所的通告! | | 西普尼以招股上限定价29.6港元，一手市值2960港元。甲组全部抽签，乙二才能稳中一手，申购顶头槌用10倍融资还需要158万本金，最多也就中签2手， 货值6000港元。 | | 博泰车联(02889.HK)-分配结果 | | | --- | --- | - ...

来源：环球网 【环球网财经综合报道】9月25日，奇瑞汽车正式登陆港股，当天收涨3.8%。也是在这一天，易方达基 金披露的关联交易公告显示，旗下5只基金参与奇瑞汽车H股认购，合计获配142.62万股。 易方达基金公告 其中，杨桢霄管理的易方达全球医药行业获配最多，达72.52万股，获配金额2230万港元；李剑锋管理 的易方达全球优质企业获配25.26万股，获配金额776.74万港元；张清华管理的易方达全球配置获配7.25 万股，获配金额222.94万港元；郑希管理的易方达全球成长精选获配25.5万股，获配金额784.12万港 元。 且此次奇瑞汽车IPO定价为30.75港元/股，共发行约2.97亿股H股。其中，香港公开发售约0.297亿股，占 比10%；国际发售约2.677亿股，占比90%，并设有15%超额配股权。从招股书来看，奇瑞此次除引入13 名基石投资者外，还吸引了CICC FT、华泰资本投资、易方达香港、广发国际、惠理基金、广发全球资 本、中信证券国际、华夏基金香港、华夏基金、招银国际资管、博时基金等多家资管机构参与竞价。其 中，中信证券国际获配最多，达420.72万股。 实际上，易方达基金并非首次涉足港 ...

Company Overview - Aokas Electric, established in 1994, specializes in the design, research, production, sales, and service of high-quality home and central air conditioning systems [1] - The company has a product matrix primarily focused on home and central air conditioning, with brands including "Aokas AUX," "Hua Suan," and "AUFIT," as well as high-end brands like ShinFlow [1] Financial Highlights - Revenue growth from 19,528 million RMB in 2022 to 24,832 million RMB in 2023, with a projected increase to 29,759 million RMB in 2024, reflecting a compound annual growth rate (CAGR) of 27.2% from 2022 to 2023 and 19.8% from 2023 to 2024 [4] - Gross profit increased from 4,150 million RMB in 2022 to 5,422 million RMB in 2023, with a gross margin of approximately 21% [4] - Adjusted net profit rose from 1,442 million RMB in 2022 to 2,487 million RMB in 2023, with a net profit margin of around 10% [4] Market Position - Aokas ranks as the fifth largest air conditioning provider globally, with a market share of 7.1% in 2024 [2][5] - The company holds the number one position in China's mass market for home air conditioning, with a market share of 25.7% in 2024 [5] Global Expansion Strategy - Since 2018, Aokas has been implementing a global strategy, establishing overseas sales companies and local teams in regions such as Malaysia, Thailand, the USA, and Saudi Arabia [2] - The company's overseas revenue share increased from 42.9% in 2022 to 49.3% in 2024, further rising to 57.1% in Q1 2025 [8] Cost Efficiency and Channel Strategy - Aokas has adopted a streamlined distribution model since 2017, allowing dealers to connect directly with factories via an app, enhancing price competitiveness and inventory turnover [6] - The company maintains a stable gross margin of around 21% and a net margin of approximately 10%, with higher margins in the central air conditioning segment [7] Investment Highlights - The upcoming IPO is expected to raise between 3.312 billion HKD and 3.606 billion HKD, with a market capitalization estimated between 24.915 billion HKD and 27.126 billion HKD [1] - The founder, Zheng Jianjiang, controls approximately 96.36% of the voting rights, indicating a concentrated ownership structure [9]